Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing

Abstract

Endothelial cells are a promising target for cancer gene somes ACHx/DC-Chol/DOPE and ACO/DC-Chol/DOPE. therapy because neoangiogenesis is vital for the supply of Endothelial cells transfected with HSV-thymidine kinase oxygen and nutrients to solid tumours. However, endousing DC-Chol/DOPE demonstrated 3 log 10 increased thelial cells have been reported to be difficult to transfect. cytotoxicity compared with controls when exposed to the We demonstrate high rates of transfection with the reporter prodrug ganciclovir, thereby demonstrating significant biogene pSV40␤gal using DC-Chol/DOPE cationic liposomes logical effect. and lower rates with the novel polyamine cationic lipo-

A new cholesterol derivative suitable for transfecting certain type of cells in the presence of 10% serum

“…In the former cell line, maximum transfection efficiency in the presence of 10% sera was attained with DC-Chol:DOPE liposomes followed by DDAB:DOPE ( Fig 4B); in the latter cell line, DC-Chol:DOPE and BGTC:DOPE liposomes appear to work best under the transfection conditions used (Fig 4C; also see Ref. 22). Thus, Arg-Chol: DOPE liposomes yielded a high expression of reporter gene in epithelial melanoma cells as opposed to less prominent expression in endothelium-derived Renca and ECV304 cells.…”

Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery

“…In previous studies the transfection efficiency was not significantly greater with ACHx formulated liposomes than DCChol:DOPE liposomes. 29, 52 Yet we have shown that a significant therapeutic effect was obtained in mice with CIA when ACHx/DCChol:DOPE liposomes were used for in vivo gene delivery.…”

Advances in Liposomal Drug Delivery System: Fascinating Types and Potential Applications

“…No Golgi dilation was observed. Depending upon the nature and difference in various human tumor cell lines, stealth monensin liposomes increase the activity of Doxorubicin by 2-2400 times [9]. Ehrlich tumor cells were inhibited using liposomes containing doxorubicin in the ratio of 100:100:60:4.…”